Literature DB >> 16736511

African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men.

Ricardo F Sanchez-Ortiz1, Patricia Troncoso, Richard J Babaian, Josep Lloreta, Dennis A Johnston, Curtis A Pettaway.   

Abstract

BACKGROUND: Although prostate cancer (PC) mortality disproportionately affects African-American (AA) men, limited data exist comparing the pathologic characteristics of white and AA patients with nonpalpable PC (clinical stage T1c).
METHODS: The authors reviewed the radical prostatectomy (RP) specimens from 37 consecutive AA men with clinical stage T1c PC and 35 white men who were matched for age, clinical stage, serum prostate-specific antigen (PSA) level, year of surgery, prostate weight, and prostate biopsy strategy. Pathologic characteristics were compared after mapping tumor foci and calculating tumor volumes by using computer software.
RESULTS: For AA men, the median age (57.7 years), mean serum PSA level (9.3 ng/mL), mean prostate weight (43 g), and biopsy strategy (73% sextant) were matched with the cohort of 35 white men (median age, 57.1 years; mean PSA, 9.3 ng/mL;, mean prostate weight, 43 g; biopsy strategy, 66% sextant). Despite similar biopsy characteristics between the 2 groups (Gleason score > or =7 in 43% of AA men vs. 37% of white men), AA men exhibited significantly higher prostatectomy Gleason scores (> or =7 in 76% of AA men vs. 34% of white men; P = .01). AA men also had a higher mean tumor volume (1.82 cm3 vs. 0.72 cm3; P = .001) and had 2.8 times more tumor per ng/mL of serum PSA (0.22 cm3 per ng/mL vs. 0.079 cm3 per ng/mL; P = .001).
CONCLUSIONS: Compared with a cohort of white men with similar clinical features at the time of biopsy, AA men with nonpalpable PC had higher prostatectomy Gleason scores, greater cancer volume, and greater tumor volume per ng/mL of serum PSA. These data provide additional support for the concept of early PC detection using a serum PSA threshold of 2.5 ng/mL for biopsy among AA men. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736511     DOI: 10.1002/cncr.21954

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  43 in total

1.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.

Authors:  Isaac J Powell; Cathryn H Bock; Julie J Ruterbusch; Wael Sakr
Journal:  J Urol       Date:  2010-03-17       Impact factor: 7.450

2.  Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer.

Authors:  Kelvin A Moses; Heather Orom; Alicia Brasel; Jacquelyne Gaddy; Willie Underwood
Journal:  Urol Oncol       Date:  2016-05-06       Impact factor: 3.498

3.  The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men.

Authors:  Michael Kongnyuy; Abhinav Sidana; Arvin K George; Akhil Muthigi; Amogh Iyer; Michele Fascelli; Meet Kadakia; Thomas P Frye; Richard Ho; Francesca Mertan; M Minhaj Siddiqui; Daniel Su; Maria J Merino; Baris Turkbey; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  Urol Oncol       Date:  2016-02-20       Impact factor: 3.498

4.  Association Between Serum Testosterone and Serum PSA Among Men With and Without Partial Androgen Deficiency.

Authors:  A Shukla; B Sharda; S Sharma; S Bhardwaj; U Kailash; R Kalani; L Satyanarayana; A Shrivastava
Journal:  Indian J Clin Biochem       Date:  2018-07-31

5.  Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.

Authors:  S Scott Sutton; E David Crawford; Judd W Moul; James W Hardin; Eric Kruep
Journal:  World J Urol       Date:  2016-01-11       Impact factor: 4.226

Review 6.  African-American Prostate Cancer Disparities.

Authors:  Zachary L Smith; Scott E Eggener; Adam B Murphy
Journal:  Curr Urol Rep       Date:  2017-08-14       Impact factor: 3.092

7.  MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer.

Authors:  Li Zhang; Jianghua Wang; Yongquan Wang; Yiqun Zhang; Patricia Castro; Longjiang Shao; Arun Sreekumar; Nagireddy Putluri; Nilanjan Guha; Saligrama Deepak; Arunkumar Padmanaban; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2016-08-30       Impact factor: 12.701

8.  Copy number and gene expression differences between African American and Caucasian American prostate cancer.

Authors:  Amy E Rose; Jaya M Satagopan; Carole Oddoux; Qin Zhou; Ruliang Xu; Adam B Olshen; Jessie Z Yu; Atreya Dash; Jerome Jean-Gilles; Victor Reuter; William L Gerald; Peng Lee; Iman Osman
Journal:  J Transl Med       Date:  2010-07-22       Impact factor: 5.531

9.  Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci.

Authors:  John W Davis; Jeri Kim; John F Ward; Xuemai Wang; Hiro Nakanishi; R Joseph Babaian; Patricia Troncoso
Journal:  BJU Int       Date:  2009-11-03       Impact factor: 5.588

10.  Impact of socioeconomic factors on prostate cancer outcomes in black patients treated with surgery.

Authors:  Atreya Dash; Peng Lee; Qin Zhou; Jerome Jean-Gilles; Samir Taneja; Jaya Satagopan; Victor Reuter; William Gerald; James Eastham; Iman Osman
Journal:  Urology       Date:  2008-03-04       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.